Literature DB >> 25004829

Expression of thioredoxins and glutaredoxins in human hepatocellular carcinoma: correlation to cell proliferation, tumor size and metabolic syndrome.

A Mollbrink1, R Jawad2, A Vlamis-Gardikas3, P Edenvik1, B Isaksson1, O Danielsson2, P Stål1, A P Fernandes2.   

Abstract

Thioredoxins (Trx) and glutaredoxins (Grx) are thiol oxidoreductases that are ubiquitously expressed, and are involved in several biological processes. The expression of thioredoxins and glutaredoxins is induced in many neoplasms, and correlates with prognosis in gallbladder and colorectal carcinoma. The aim of the present study was to examine the expression pattern of these proteins (redoxins) in hepatocellular carcinoma (HCC) and to correlate their levels with clinical features. Paraffin-embedded tissues from 25 patients resected for HCC and 15 patients resected for colorectal carcinoma (CRC) liver metastases were analyzed with immunohistochemistry. Our results showed that Trx1, Trx2 and Grx5 were upregulated in HCCs as compared to the respective surrounding liver. In comparison, almost all redoxins were upregulated in CRC liver metastases, with Trx1 and Grx3 being significantly more increased in the CRC liver metastases than in the primary HCC tumors. In HCC, Trx1 correlated significantly with cell proliferation, and with a trend towards increased levels with micro-vascular invasion, while expression of Trx2 decreased with tumor size. Trx1 levels were lower in tumors of males, smokers, and patients with high alcohol consumption. Grx2 levels were significantly higher in patients with metabolic syndrome. In conclusion, this study illustrates specific correlations of individual redoxins to clinical features of HCC, and implicates the redoxins in the pathogenesis of HCC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25004829     DOI: 10.1177/039463201402700204

Source DB:  PubMed          Journal:  Int J Immunopathol Pharmacol        ISSN: 0394-6320            Impact factor:   3.219


  15 in total

1.  Prognostic Values of BolA Family Member Expression in Hepatocellular Carcinoma.

Authors:  Dong Wang; ZhiMing Wang; YiMing Tao
Journal:  Biomed Res Int       Date:  2022-08-16       Impact factor: 3.246

2.  Clinical Significance of the Thioredoxin System and Thioredoxin-Domain-Containing Protein Family in Hepatocellular Carcinoma.

Authors:  Sang Yeon Cho; Sungha Kim; Mi-Ju Son; Woo Sun Rou; Seok Hyun Kim; Hyuk Soo Eun; Byung Seok Lee
Journal:  Dig Dis Sci       Date:  2018-10-04       Impact factor: 3.199

3.  Oxidative stress measured by thioredoxin reductase level as potential biomarker for prostate cancer.

Authors:  Weibing Zhang; Xinming Zheng; Xinghuan Wang
Journal:  Am J Cancer Res       Date:  2015-08-15       Impact factor: 6.166

4.  Thioredoxin reductase: a novel, independent prognostic marker in patients with hepatocellular carcinoma.

Authors:  Chunyan Li; Yan Peng; Binglang Mao; Kun Qian
Journal:  Oncotarget       Date:  2015-07-10

5.  Comparison of Serum Total Valproic Acid Levels and %CDT Values in Chronic Alcohol Addictive Patients in an Italian Clinic: A Retrospective Study.

Authors:  Vincenzo De Iuliis; Raimondo Gelormini; Mariarosaria Flacco; Giuseppe Moriello; Marika Caruso; Eugenia Barone; Maria Golato; Elena Toniato; Pio Conti; Stefano Martinotti
Journal:  Drugs Real World Outcomes       Date:  2016-03

Review 6.  Accuracy of novel diagnostic biomarkers for hepatocellular carcinoma: An update for clinicians (Review).

Authors:  Patrick Reichl; Wolfgang Mikulits
Journal:  Oncol Rep       Date:  2016-06-01       Impact factor: 3.906

7.  Morphological alterations and redox changes associated with hepatic warm ischemia-reperfusion injury.

Authors:  Rim Jawad; Melroy D'souza; Lisa Arodin Selenius; Marita Wallenberg Lundgren; Olof Danielsson; Greg Nowak; Mikael Björnstedt; Bengt Isaksson
Journal:  World J Hepatol       Date:  2017-12-08

8.  Tumor-initiating cells of breast and prostate origin show alterations in the expression of genes related to iron metabolism.

Authors:  Zuzana Rychtarcikova; Sandra Lettlova; Veronika Tomkova; Vlasta Korenkova; Lucie Langerova; Ekaterina Simonova; Polina Zjablovskaja; Meritxell Alberich-Jorda; Jiri Neuzil; Jaroslav Truksa
Journal:  Oncotarget       Date:  2017-01-24

9.  Thioredoxin Reductase as a Novel and Efficient Plasma Biomarker for the Detection of Non-Small Cell Lung Cancer: a Large-scale, Multicenter study.

Authors:  Suofu Ye; Xiaofeng Chen; Yi Yao; Yueqin Li; Ruoxuan Sun; Huihui Zeng; Yongqian Shu; Hanwei Yin
Journal:  Sci Rep       Date:  2019-02-25       Impact factor: 4.379

10.  Glutaredoxin 3 promotes nasopharyngeal carcinoma growth and metastasis via EGFR/Akt pathway and independent of ROS.

Authors:  Feng He; Lili Wei; Wenqi Luo; Zhipeng Liao; Bo Li; Xiaoying Zhou; Xue Xiao; Jingping You; Yufeng Chen; Shixing Zheng; Ping Li; Mariko Murata; Guangwu Huang; Zhe Zhang
Journal:  Oncotarget       Date:  2016-06-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.